The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Single, double and even triple-payload ADCs will be presented at the meeting.
Talapro-3 could help move Talzenna into earlier prostate cancer.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
The company reveals its anti-GPRC5D T-cell engager.
First human data on MK-2010 are imminent.
The company’s TRPV1 antagonist looks doomed.
